PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1733945
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1733945
Global Immunology Market to Reach US$154.4 Billion by 2030
The global market for Immunology estimated at US$113.5 Billion in the year 2024, is expected to reach US$154.4 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Diagnostic Testing Equipment, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$88.0 Billion by the end of the analysis period. Growth in the Biomarkers segment is estimated at 3.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$30.9 Billion While China is Forecast to Grow at 8.6% CAGR
The Immunology market in the U.S. is estimated at US$30.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$31.2 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.
Global Immunology Market - Key Trends & Drivers Summarized
Why Is Immunology Central to Understanding and Treating Complex Diseases?
Immunology-the study of the immune system and its response to pathogens, cancer cells, allergens, and internal dysregulation-is at the core of a vast range of medical research and therapeutic development. The discipline has expanded far beyond infectious disease and now encompasses autoimmunity, oncology, transplant biology, neuroinflammation, and chronic inflammatory diseases. With the rise of precision medicine, understanding individual immune responses has become critical to tailoring effective treatments.
Advancements in immunology have enabled breakthroughs such as monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapy. Additionally, immunomodulators and cytokine-targeting biologics are transforming the treatment of conditions like rheumatoid arthritis, psoriasis, asthma, and multiple sclerosis. Immunology is also foundational to vaccine development, particularly for emerging viral threats and for therapeutic cancer vaccines under development in immuno-oncology.
How Are Research and Drug Development Platforms Driving Immunology Innovation?
Technological innovation in immunology research is being driven by single-cell analysis, flow cytometry, next-generation sequencing (NGS), and advanced imaging platforms. These tools are helping researchers map immune system behavior at unprecedented resolution and uncover mechanisms of immune tolerance, inflammation, and cell-mediated immunity. AI and bioinformatics are accelerating immunogenomics and predictive modeling of immune responses to drugs and vaccines.
Pharmaceutical and biotech companies are investing heavily in immunology-focused R&D to discover novel biologics and cell-based therapies. Humanized mouse models, organ-on-chip technologies, and personalized immunoprofiling are being used to simulate and study patient-specific immune responses in vitro. Clinical trials in autoimmune diseases and immuno-oncology continue to drive therapeutic pipeline growth, particularly for mAbs, checkpoint inhibitors, and bispecific T-cell engagers (BiTEs).
Which Diseases and Markets Are Prioritizing Immunological Solutions?
Autoimmune diseases such as lupus, type 1 diabetes, and Crohn’s disease are key areas of immunological research, alongside cancers such as melanoma and non-small-cell lung cancer that respond well to immune checkpoint blockade. Allergies, asthma, and transplant rejection also represent major therapeutic areas addressed through immunology-based interventions. Additionally, emerging interest in neuroimmunology is linking immune responses to neurodegenerative disorders like Alzheimer’s and Parkinson’s.
North America leads in immunology research and therapeutic development, supported by academic research hubs and a strong biopharmaceutical pipeline. Europe follows closely with advanced regulatory and clinical research ecosystems. Asia-Pacific is rapidly growing, particularly in immunotherapy development and vaccine manufacturing, led by China, India, and Japan. Government-backed research programs, biologics investment, and the COVID-19 response have accelerated immunology activity across all major regions.
The Growth in the Immunology Market Is Driven by Several Factors…
The growth in the immunology market is driven by several factors including rising prevalence of autoimmune and inflammatory diseases, technological advances in immunoassay platforms and cellular analysis, and strong therapeutic pipelines for immune-modulating drugs. Biologics development, immune checkpoint inhibitors, and precision-targeted therapies are driving clinical breakthroughs. Increased funding for immunological R&D, global vaccine expansion, and partnerships between academia and industry are reinforcing market momentum.
From an end-use perspective, expanding demand for immunotherapy in oncology, increased use of biologics in autoimmune conditions, and the growing role of immunological biomarkers in diagnostics are key growth levers. The emergence of personalized immunology, innovations in vaccine adjuvants, and broader understanding of the microbiome-immune axis are also contributing to long-term industry expansion. As the immune system becomes central to 21st-century medicine, the global immunology market is set for sustained, innovation-led growth.
SCOPE OF STUDY:
The report analyzes the Immunology market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product Type (Diagnostic Testing Equipment, Biomarkers, Biopharmaceuticals); Application (Allergy & Hypersensitivity, Autoimmune Disease, Infectious Disease, HIV & AIDS, Other Applications); End-Use (Hospitals & Clinics, Pharma & Biotech Companies, Diagnostic Laboratories, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 32 Featured) -
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.